Videos/Articles

Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI

How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment

The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare

Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT

Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT

SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment

Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough

Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update

Benzinga – A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing

Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds

Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study

The Market Herald – Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil

Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned Phase 2b Chronic Cough Study of Ifenprodil

Benzinga – Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One

Proactive Investors Interview – Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program

Wonderland 2022 Recap: Algernon Pharmaceuticals

The National Investor – Repurposing Drugs For New Needs — Algernon Pharmaceuticals Inc. (CSE-AGN; OTCQB-AGNPF)

Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon for Algernon Pharmaceuticals DMT Study

MarketOne Video Interview with CEO Christopher J. Moreau – Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke

Psychedelic Finance – Feature: Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals

Drug Discovery and Development – Why Algernon Believes it is the Janis Joplin of Psychedelic Medicine Companies

Psychedelic Finance – Feature: Algernon Pharmaceuticals

Market One – Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 Study of DMT for Stroke

Born2Invest – Algernon Pharmaceuticals Is Developing Pioneering Treatments With a Cost-Efficient R&D Pipeline

BNN Bloomberg – In a sector ripe for revival, Algernon’s development pipeline positions it well.

Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Yale Clinical Trial for DMT Phase 2 Depression Study

Psychedelic Spotlight – Prolonged DMT Infusions could be a Breakthrough for Stroke Patients

Drug Discovery and Development – DMT pioneer Rick Strassman weighs in on psychedelic hope and hype

High TImes – New Research Exploring DMT as a Treatment for Stroke

Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Business Update – Ifenprodil & DMT Trials

Mugglehead Magazine – Algernon receives approval to conduct DMT study in the Netherlands

Pulmonary Fibrosis News – Orphan Drug Status Sought for NP-120 to Treat IPF With Cough

Proactive Investors Interview – Algernon Pharmaceuticals Gains Approval for Phase 1 Clinical Study of DMT for Treatment of Stroke

Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?

Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough

Streetwise Reports – Hedge Fund Doubles Position in Biotech Co.